yup, probably picked up by his team and Berkshire Hathway’s only biotech buy so far .... and one of the non- performing one stocks in his portfolio
Biotech is high risk investment... 50:50 could go either way and he is known for safer investment and holding
Would you blindly hold a biotech even if they keep flipping negative results and unable to deliver a marketable product?
Anyway, its MSB thread not Berkshire Hathways or Biogen’s
Mesoblast Investor losses, page-73
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |